Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 29, 2023

OncoVent signs agreement with Orient EuroPharma for oregovomab

Shenzhen Hepalink Pharmaceutical Group’s subsidiary OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.

OncoVent signs agreement with Orient EuroPharma for oregovomab